Aegle Therapeutics

Aegle Therapeutics is a biotech company. It has raised $6.5M across 1 round, most recently a $6.5M Series A in September 2020.

Harnessing the regenerative, immunomodulatory, and anti-inflammatory potential of MSC-derived Extracellular Vesicles

Total Funding
$6.5M
Last Round
$6.5M Series ASep 2020
Rounds
1

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 1 funding round and 3 investors for this company. The full record is or through the API.

About

Aegle Therapeutics develops cell-free extracellular vesicle therapies for rare diseases, including dystrophic epidermolysis bullosa and other severe dermatological disorders. Its therapeutic approach uses extracellular vesicles to deliver a natural biomolecular payload to treat disorders with significant unmet medical need. Its AGLE-102 candidate contains vesicles, including exosomes, isolated from mesenchymal stem cells using proprietary harvesting technology.

Summary

It has raised $6.5M in total across 1 round, most recently a $6.5M Series A round in Sep 2020. Investors include Tellus BioVentures, DeepWork Capital and New World Angels.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Data from Indexed.vcUpdated
Series ASeries ASep 2020
$6.5M

Investors

Similar Companies

Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
ArsenalBio

Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...

San Francisco, United States201–500Biotech, Life Sciences
Series CTotal funding$955.0MSep 2024
Lyell ImmunopharmaIPO

Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...

South San Francisco, United States201–500Biotech, Healthcare
Venture RoundTotal funding$884.0MJul 2025
Tessera Therapeutics

Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...

Somerville, United States201–500Biotech, Genomics
Corporate RoundTotal funding$730.0MDec 2025
OricIPO

San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...

South San Francisco, United States51–200Biotech, Healthcare
Private EquityTotal funding$647.0MFeb 2026
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Aegle Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/aegle-therapeutics"><img src="https://indexed.vc/api/badge/company/aegle-therapeutics" alt="Aegle Therapeutics on Indexed.vc" width="260" height="76" /></a>